However, the problem with long-term therapy with the mTOR inhibitor everolimus is that it reduces the size of tumors but does not cure them, thereby increasing the chances of gonadal dysfunction, interstitial lung disease, and immunosuppression-related complications (25). This evidence concerns the gene MTOR and interstitial lung disease.